22 October 2024 The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain. 21 October 2024
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Pharmaceutical Research and Manufacturers of America (PhRMA) says it has submitted comments to the Office of the United States Trade Representative (USTR) to inform the agency’s 2025 National Trade Estimate (NTE) Report on Foreign Trade Barriers. 21 October 2024
More than 22,500 scientists, clinicians, advocates, and other attendees are on their way to a congress center in Atlanta for the 110th Annual Meeting of the American Association for Cancer Research (AACR). 28 March 2019
Kyoto University Innovation Capital and Japanese drugmaker Sumitomo Dainippon Pharma today announced the establishment of AlphaNavi Pharma as a carve-out business venture from Sumitomo Dainippon Pharma, and allocated new shares to third-parties. 28 March 2019
The US Food and Drug Administration on Wednesday approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism. 28 March 2019
The UK Supreme Court has handed down a unanimous decision in a case between generics firm Actavis and Eli Lilly subsidiary ICOS, finding that discoveries from routine research can be rewarded with a patent. 27 March 2019
The National Institute of Care and Health Excellence (NICE) has issued a final appraisal determination (FAD) recommending Steglatro as a monotherapy in British adults with type 2 diabetes (T2DM) for whom metformin is contraindicated or not tolerated, or as part of a dual therapy with metformin. 27 March 2019
Privately-held Purdue Pharma has agreed to pay for the establishment of the USA’s leading addiction research center in a settlement with the state of Oklahoma over the opioid crisis that its drug Oxycontin (oxycodone) contributed to. 27 March 2019
Most commercial executives in the industry thought the discussions over Obamacare were finally at an end, after a monthslong war of attrition between the White House and Congress early in Mr Trump’s presidency. They may need to think again. 27 March 2019
New research highlights the continued differences between the USA and European to drug approval, and the need for a global approach, to drug development to ensure success across both continents. 27 March 2019
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). 27 March 2019
Several multinationals in India continue to be sole sellers of certain cancer drugs even after product patents expire, with generic companies unwilling or unable to enter the market due to various barriers including manufacturing and regulatory. 27 March 2019
A new alliance between the UK-based charities Cancer Research UK and LifeArc and Japanese drugmaker Ono Pharmaceutical will seek to discover and progress new targets in immuno-oncology. 27 March 2019
Organizers of the CPhI Japan have said that a consensus coming out of the event among drugmakers was for the removal of long-list products. 26 March 2019
Germany-based Biofrontera has entered into an agreement to acquire all shares in Cutanea Life Sciences through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co Japan as the seller. 26 March 2019
More than five years after the blood thinner Xarelto (rivaroxaban) litigation began, and with Germany’s Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals prevailing in all six cases that went to trial, the companies have reached an agreement in principle to settle in the amount of $775 million. 25 March 2019
In what seems to be rare these days, USA-based Avanir Pharmaceuticals has presented positive new late-stage data for its AVP-786 in the Alzheimer’s setting. 25 March 2019
AstraZeneca’s Forxiga (dapagliflozin) has become the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes. 25 March 2019
The share of domestic drugs in the public procurements in Russia has reached record figures for the last four years and currently continues to grow, according to recent statistics, published by the Russian Ministry of Health and statements of some local analysts in the field of pharmaceutics. 25 March 2019
Péter Holchacker, director of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), has said that the country’s medicines budget is 20 billion Hungarian forint ($71 million) behind what it was a decade ago. 25 March 2019
Botox (onabotulinumtoxinA) manufacturer Allergan has accepted calls to shake up its management structure, agreeing to create a new position to stand alongside the chief executive at the time of the next leadership change. 25 March 2019
A company that is seeking non-opioid solutions for acute pain is a step further from finding one after receiving a second complete response letter (CRL) relating to one of its candidates. 25 March 2019
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.